In the 171 patients evaluated for efficacy, 4 (%) experienced a complete response (CR) and 40 (%) a partial response (PR), with the overall response rate of %. Ninety patients (%) had stable disease (SD), with 25 having SD for at least 24 weeks. The clinical benefit (CR + PR + SD > or = 24 weeks) was shown in 69 (%) patients. Progressive disease (PD) was shown in 37 (%) patients. The untreated patients had a higher objective response rate (%) than the retreated ones (%) with significant difference (P = 7). The response rates for soft-tissue, bone involvement and visceral metastasis were %, %, and % (P = ). There was no significant difference in different ages, time of menopause, disease-free interval or receptor status (P > ). Drug-related adverse events were gastric discomfort (%), malaise (%), nausea (%), hot flushes (%) and dysphoria (%). Other side reactions and abnormal laboratory parameters were observed occasionally which were irrelevant.
If chemotherapy or an aromatase inhibitor (or both) is part of your breast cancer treatment plan, you should talk to your doctor about your bone health. Ask your doctor about monitoring your bone health during and after treatment. Also ask whether treatment with a bone-strengthening medicine such as Actonel or one of the other bisphosphonate medicines might help improve your bone health or at least minimize the negative effects of treatment on your bones. In addition to medical treatment, there are a number of nutrition and lifestyle changes that you can take to improve the health of your bones. Visit the Bone Health section to learn about these changes and much more about bone health.